HLA class II histocompatibility antigen, DRB1-3 beta chain (HLA-DRB1*03:01)

HLA class II histocompatibility antigen, DRB1-3 beta chain (specifically the HLA-DRB1*03:01 allele) is a highly polymorphic protein that constitutes the beta subunit of the HLA-DR heterodimer, a central component of the human major histocompatibility complex (MHC) class II. Expressed primarily on professional antigen-presenting cells such as dendritic cells, B cells, and macrophages, it functions by binding and presenting exogenous peptide antigens to CD4+ T-helper cells to initiate and regulate adaptive immune responses. This specific allele is a major genetic determinant for susceptibility to several autoimmune disorders, including systemic lupus erythematosus (SLE), type 1 diabetes, Graves' disease, and autoimmune hepatitis, likely due to its role in presenting self-peptides or its involvement in non-canonical inflammatory signaling pathways. In drug development, it is considered a therapeutic target for immunomodulatory agents that aim to disrupt the presentation of pathogenic antigens or induce immune tolerance. Current clinical agents like hydroxychloroquine and glatiramer acetate modulate MHC class II-mediated pathways, while research into allele-specific small molecules and peptide-based inhibitors is ongoing to provide more targeted therapies for HLA-DR3-associated conditions.

Other names

HLA-DRB1*03DR3MHC class II antigen DRB1*03Human leukocyte antigen DRB1*03:01DRw3HLA-DRB1*03:01:01

Competitive inhibition of the MHC class II peptide-binding groove, interference with endosomal antigen processing and loading, and modulation of T-cell costimulatory signals.